Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry
Authors' conclusion
In RA, chronic concomitant GC treatment and patient age are associated with JAK inhibitor discontinuation due to lack of effectiveness and ADRs, respectively.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with JAKi, JAGUAR Registry
- Participants
- 435 treatment episodes
- Exposure
- Factors associated with JAKi retention
- Tofacitinibn = 118
- Baricitinibn = 181
- Upadacitinibn = 80
- Filgotinibn = 56
- Outcome
- Treatment retention; discontinuation due to lack of effectiveness and ADRs
- Follow-up
- 1 and 4 years
Methodological detailsmulticentre registry, Cox regression, Kaplan-Meier
- Multicentre registry
- Cox regression
- Kaplan-Meier
Main finding
As reported in the abstract
Discontinuation rates (all JAKi) · 1 year
Due to lack of effectiveness
23.0%
Due to adverse drug reactions (ADRs)
17.0%
Due to other reasons
2.3%
Observational data: associations, not effects.
Further findings
Discontinuation rates (all JAKi) · 4 years
- Due to lack of effectiveness
- 32.9%
- Due to ADRs
- 19.5%
- Due to other reasons
- 5.5%
Discontinuation due to lack of effectiveness by glucocorticoid (GC) duration (>6 vs ≤6 months)
- Chronic concomitant GC associated with discontinuation for lack of effectiveness
- P = 0.007
- >6 months vs ≤6 months, 1 year
- 29.1% vs 18.8%
- >6 months vs ≤6 months, 4 years
- 50.5% vs 32.5%
Safety
- Age associated with discontinuation due to ADRs
- P = 0.003
- ≥65 vs <65 years, 1 year
- 25.6% vs 14.5%
- ≥65 vs <65 years, 4 years
- 35.3% vs 17.4%
Original publication
Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. RMD Open. Published 31 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →